Interventions to prevent HIV and hepatitis C in people who inject drugs: A review of reviews to assess evidence of effectiveness

International Journal of Drug Policy

Volumn 25, Issue 1, 2014, Pages 34-52

  MacArthur, Georgina J ^a   van Velzen, Eva ^b   Palmateer, Norah ^c   Kimber, Jo ^d   Pharris, Anastasia ^e   Hope, Vivian ^f,g   Taylor, Avril ^h   Roy, Kirsty ^c   Aspinall, Esther ⁱ   Goldberg, David ^c   Rhodes, Tim ^f   Hedrich, Dagmar ^j   Salminen, Mika ^e   Hickman, Matthew ^a   Hutchinson, Sharon J ^c,h  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NHS Sutton and Merton London KSS Specialty School of Public Health   (United Kingdom)

^c HEALTH PROTECTION SCOTLAND   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

ⁱ UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^j EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

more..

Author keywords

Harm reduction; Hepatitis C; HIV; People who inject drugs; Review

Indexed keywords

OPIATE;

DISEASE TRANSMISSION; DRUG ABUSE; HARM REDUCTION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NEEDLE; OPIATE SUBSTITUTION TREATMENT; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYRINGE; SYSTEMATIC REVIEW;

HARM REDUCTION; HEPATITIS C; HIV; PEOPLE WHO INJECT DRUGS; REVIEW;

HARM REDUCTION; HEPATITIS C; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84892955131     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2013.07.001     Document Type: Review

References (235)

1. Abbott P.J., Moore B.A., Weller S.B., Delaney H.D. AIDS risk behavior in opioid dependent patients treated with community reinforcement approach and relationships with psychiatric disorders. Journal of Addictive Diseases 1998, 17:33-48.
2. Avants S.K., Margolin A., Kosten T.R., Rounsaville B.J., Schottenfeld R.S. When is less treatment better?. The role of social anxiety in matching methadone patients to psychosocial treatments. Journal of Consulting & Clinical Psychology 1998, 66:924-931.
3. Avants S.K., Margolin A., Sindelar J.L., Rounsaville B.J., Schottenfeld R., Stine S., et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: A comparison of clinical efficacy and cost. American Journal of Psychiatry 1999, 156:27-33.
4. Avants S.K., Margolin A., Usubiaga M.H., Doebrick C. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy. Journal of Substance Abuse Treatment 2004, 26:67-78.
5. Baker A., Heather N., Wodak A., Dixon J., Holt P. Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. AIDS 1993, 7:247-256.
6. Baker A., Kochan N., Dixon J., Wodak A., Heather N. HIV risk-taking behaviour among injecting drug users currently, previously and never enrolled in methadone treatment. Addiction 1995, 90:545-554.
7. Ball A.L., Rana S., Dehne K.L. HIV prevention among injecting drug users: Responses in developing and transitional countries. [Review] [63 refs]. Public Health Reports 1998, 113(Suppl. 81).
8. Bastos F.I., Strathdee S.A. Evaluating effectiveness of syringe exchange programmes: Current issues and future prospects. Social Science & Medicine 2000, 51:1771-1782.
9. Batki S.L., Sorensen J.L., Gibson D.R., Maude-Griffin P. HIV-infected i.v. drug users in methadone treatment: Outcome and psychological correlates-a preliminary report. NIDA Research Monograph 1989, 95:406.
10. Bell D.M. Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview. American Journal of Medicine 1997, 102:9-15.
11. Benninghoff F., Dubois-Arber F. Résultats de l'étude de la clientèle de Cactus BIEL/BIENNE 2001. Lausanne: Institut universitaire de médecine sociale et préventive 2002.
12. Benninghoff F., Solai S., Huissoud T., Dubois-Arber F. Evaluation de Quai 9 "Espace d'accueil et d'injection" à Genève; periode 12/2001-12/2000. Lausanne; Institut universitaire de médicine sociale et préventive 2003.
13. Bluthenthal R.N., Kral A.H., Erringer E.A., Edlin B.R. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland California, 1992 to 1995. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 18:505-511.
14. Bluthenthal R.N., Kral A.H., Gee L., Erringer E.A., Edlin B.R. The effect of syringe exchange use on high-risk injection drug users: A cohort study. AIDS 2000, 14:605-611.
15. Bluthenthal R.N., Malik M.R., Grau L.E., Singer M., Marshall P., Heimer R. Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. Addiction 2004, 99:1136-1146.
16. Broadhead R.S., Heckathorn D.D., Weakliem D.L., Anthony D.L., Madray H., Mills R.J., et al. Harnessing peer networks as an instrument for AIDS prevention: Results from a peer-driven intervention. Public Health Reports 1998, 113(Suppl. 57).
17. Broadhead R.S., van Hulst Y., Heckathorn D.D. The impact of a needle exchange's closure. Public Health Reports 1999, 114:439-447.
18. Broadhead R.S., Volkanevsky V.L., Rydanova T., Ryabkova M., Borch C., van Hulst Y., et al. Peer-driven HIV interventions for drug injectors in Russia: First year impact results of a field experiment. International Journal of Drug Policy 2006, 17:379-392.
19. Brooner R., Kidorf M., King V., Beilenson P., Svikis D., Vlahov D. Drug abuse treatment success among needle exchange participants. Public Health Reports 1998, 113(Suppl. 39).
20. Bruneau J., Franco E., Lamothe F. Assessing harm reduction strategies: The dilemma of observational studies. American Journal of Epidemiology 1997, 146:1007-1010.
21. Bruneau J., Lamothe F., Franco E., Lachance N., Desy M., Soto J., et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: Results of a cohort study. American Journal of Epidemiology 1997, 146:994-1002.
22. Calsyn D.A., Saxon A.J., Freeman G., Whittaker S. Needle-use practices among intravenous drug users in an area where needle purchase is legal. AIDS 1991, 5:187-193.
23. Calsyn D.A., Saxon A.J., Freeman G., Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users. American Journal of Public Health 1992, 82:573-575.
24. Camacho L.M., Bartholomew N.G., Joe G.W., Cloud M.A., Simpson D.D. Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance. Drug & Alcohol Dependence 1996, 41:1-7.
25. Caplehorn J.R., Ross M.W. Methadone maintenance and the likelihood of risky needle-sharing. International Journal of the Addictions 1995, 30:685-698.
26. Castro F.G., Tafoya-Barazza F.M. Treatment issues with Latinos addicted to cocaine and heroin. Psychological interventions and research with Latino populations 1997, 191-216. Allyn and Bacon, Boston. J.G. Garcia, M.C. Zea (Eds.).
27. Chamot E., de Saussure P., Hirschel B., Deglon J.J., Perrin L.H. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS 1992, 6:430-431.
28. Chatham L.R., Hiller M.L., Rowan-Szal G.A., Joe G.W., Simpson D.D. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Substance Use & Misuse 1999, 34:1137-1165.
29. Chen H.T., Liao Q. A pilot study of the NGO-based relational intervention model for HIV prevention among drug users in China. AIDS Education & Prevention 2005, 17:503-514.
30. Colon H.M., Finlinson H.A., Negron J., Sosa I., Rios-Olivares E., Robles R.R. Pilot trial of an intervention aimed at modifying drug preparation practices among injection drug users in Puerto Rico. AIDS and Behavior 2009, 13:523-531.
31. Colon H.M., Robles R.R., Freeman D., Matos T. Effects of a HIV risk reduction education program among injection drug users in Puerto Rico. Puerto Rico Health Sciences Journal 1993, 12:27-34.
32. Colon H.M., Sahai H., Robles R.R., Matos T.D. Effects of a community outreach program in HIV risk behaviors among injection drug users in San Juan, Puerto Rico: An analysis of trends. AIDS Education & Prevention 1995, 7:195-209.
33. Cooper H.L.F., Des Jarlais D.C., Ross Z., Tempalski B., Bossak B., Friedman S.R. Spatial access to syringe exchange programs and pharmacies selling over the counter syringes as predictors of drug injectors' use of sterile syringes. American Journal of Epidemiology 2011, 101:1118-1125.
34. Copenhaver M.M., Johnson B.T., Lee I.C., Harman J.J., Carey M.P. Behavioral HIV risk reduction among people who inject drugs: Meta-analytic evidence of efficacy. The Journal of Substance Abuse Treatment 2006, 31:163-171.
35. Cox G.M., Lawless M.C., Cassin S.P., Geoghegan T.W. Syringe exchanges: A public health response to problem drug use. Irish Medical Journal 2000, 93:143-146.
36. Coyle S.L., Needle R.H., Normand J. Outreach-based HIV prevention for injecting drug users: A review of published outcome data. Public Health Reports 1998, 113(Suppl. 1):19-30.
37. Craine N., Hickman M., Parry J.V., Smith J., McDonald T., Lyons M. Characteristics of injecting drug users accessing different types of needle and syringe programme or using secondary distribution. Journal of Public Health 2010, 32:328-335.
38. Craine N., Hickman M., Parry J.V., Smith J., Walker A.M., Russell D., et al. Incidence of hepatitis C in drug injectors: The role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology & Infection 2009, 137:1255-1265.
39. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997, 92:999-1005.
40. De Jong W., Tsagarelli T., Schouten E. Rapid assessment of injection drug use and HIV in the Republic of Georgia. Journal of Drug Issues 1999, 29:843-860.
41. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. The Lancet 2010, 376:285-301.
42. Deren S., Davis W.R., Beardsley M., Stephanie T., Clatts M. Outcomes of a risk-reduction intervention with high-risk populations: The Harlem Aids Project. AIDS Education and Prevention 1995, 7:379-390.
43. Des Jarlais C., Perlis T., Friedman S.R., Chapman T., Kwok J., Rockwell R., et al. Behavioral risk reduction in a declining HIV epidemic: Injection drug users in New York City, 1990-1997. American Journal of Public Health 2000, 90:1112-1116.
44. Des Jarlais D., Hagan H., Friedman S., Friedmann P., Goldberg D., Frischer M. Preventing epidemics of HIV-1 among injecting drug users. Drug injecting and HIV infection: Global dimensions and local responses 1998, University College of London Press, London. G. Stimson, D.C. Des Jarlais, A. Ball (Eds.).
45. Des Jarlais D.C., Friedman S.R., Sotheran J.L., Wenston J., Marmor M., Yancovitz S.R., et al. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA 1994, 271:121-127.
46. Des Jarlais D.C., Hagan H., Friedman S.R., Friedmann P., Goldberg D., Frischer M., et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995, 274:1226-1231.
47. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Hagan H., Beatrice S., et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005, 19(Suppl. 3):S20-S25.
48. Dolan K., Kimber J., Fry C., Fitzgerald J., McDonald D., Trautmann F. Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug and Alcohol Review 2000, 19:337-346.
49. Dolan K.A., Shearer J., MacDonald M., Mattick R.P., Hall W., Wodak A.D. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence 2003, 72:59-65.
50. Donoghoe M.C., Dolan K.A., Stimson G.V. Life-style factors and social circumstances of syringe sharing in injecting drug users. British Journal of Addiction 1992, 87:993-1003.
51. Donoghoe M.C., Stimson G.V., Dolan K., Alldritt L. Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. AIDS 1989, 3:267-272.
52. Ellis S., Barnett-Page E., Morgan A., Taylor L., Walters R., Goodrich J. HIV prevention: A review of reviews assessing the effectiveness of interventions to reduce the risk of sexual transmission Health Development Agency 2003.
53. European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and Drug Addiction Prevention and control of infectious diseases among people who inject drugs. ECDC and EMCDDA guidance 2011.
54. Fisher D.G., Fenaughty A.M., Cagle H.H., Wells R.S. Needle exchange and injection drug use frequency: A randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes 2003, 33:199-205.
55. Frischer M., Elliott L. Discriminating needle exchange attenders from non-attenders. Addiction 1993, 88:681-687.
56. Gerberding J.L. Management of occupational exposures to blood-borne viruses. New England Journal of Medicine 1995, 332:444-451.
57. Gibson D.R., Brand R., Anderson K., Kahn J.G., Perales D., Guydish J. Two- to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. Journal of Acquired Immune Deficiency Syndromes 2002, 31:237-242.
58. Gibson D.R., Flynn N.M., Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001, 15:1329-1341.
59. Gibson D.R., Lovelle-Drache J., Young M., Hudes E.S., Sorensen J.L. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: Final results of randomized trials of counseling with and without HIV testing. AIDS and Behavior 1999, 3:3-12.
60. Gillies M., Palmateer N., Hutchinson S., Ahmed S., Taylor A., Goldberg D. The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: A systematic review. BMC Public Health, 2010/11/26 2010, 721.
61. Gleghorn A.A., Jones T.S., Doherty M.C., Celentano D.D., Vlahov D. Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995, 10:97-103.
62. Gleghorn A.A., Wright-De Aguero L., Flynn C. Feasibility of one-time use of sterile syringes: A study of active injection drug users in seven United States metropolitan areas. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 18(Suppl 1):S30-S36.
63. Goldberg D., Burns S., Taylor A., Cameron S., Hargreaves D., Hutchinson S. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scandinavian Journal of Infectious Diseases 2001, 33:457-461.
64. Goldberg D., Cameron S., McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Communicable Disease and Public Health 1998, 1:95-97.
65. Gossop M., Marsden J., Stewart D., Rolfe A. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence 2000, 60:275-286.
66. Gowing L., Farrell M., Bornemann R., Sullivan L., Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. [Review] [120 refs] [Update of Cochrane Database Syst Rev. 2004; (4):CD004145; PMID: 15495080]. Cochrane Database of Systematic Reviews 2008, (2):CD004145. CD004145, 2008.
67. Green T.C., Bluthenthal R.N., Singer M., Beletsky L., Grau L.E., Marshall P., et al. Prevalence and predictors of transitions to and away from syringe exchange use over time in 3 US cities with varied syringe dispensing policies. Drug and Alcohol Dependence 2010, 111:74-81.
68. Greenfield L., Bigelow G.E., Brooner R. Validity of intravenous drug abusers' self-reportd changes in HIV high-risk drug use behaviors. Drug and Alcohol Dependence 1995, 39:91-98.
69. Grella C.E., Anglin M.D., Rawson R., Crowley R., Hasson A. What happens when a demonstration project ends. Consequences for a clinic and its clients. Journal of Substance Abuse 1996, 13:249-256.
70. Groseclose S.L., Weinstein B., Jones T.S., Valleroy L.A., Fehrs L.J., Kassler W.J. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers-Connecticut, 1992-1993. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995, 10:82-89.
71. Guydish J., Bucardo J., Clark G., Bernheim S. Evaluating needle exchange: A description of client characteristics, health status, program utilization, and HIV risk behavior. Substance Use & Misuse 1998, 33:1173-1196.
72. Guydish J., Clark G., Garcia D., Burcardo J. Evaluation of needle exchange using street-based survey methods. Journal of Drug Issues 1995, 25:33-41.
73. Hagan H., Des Jarlais D.C., Friedman S. Risk for human immunodeficiency virus and hepatitis b virus in users of the Tacoma syringe exchange program 1994, National Academy Press, Washington D.C.
74. Hagan H., Des Jarlais D.C., Purchase D., Friedman S.R., Reid T., Bell T.A. An interview study of participants in the Tacoma, Washington, syringe exchange. Addiction 1993, 88:1691-1697.
75. Hagan H., Jarlais D.C., Friedman S.R., Purchase D., Alter M.J. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. American Journal of Public Health 1995, 85:1531-1537.
76. Hagan H., McGough J.P., Thiede H., Weiss N.S., Hopkins S., Alexander E.R. Syringe exchange and risk of infection with hepatitis B and C viruses. American Journal of Epidemiology 1999, 149:203-213.
77. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. Journal of Infectious Disease 2011, 204:74-83.
78. Hagan H., Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. Journal of Urban Health 2000, 77:369-382.
79. Hallinan R., Byrne A.A.J., Dore G.J. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Australian and New Zealand Journal of Public Health 2004, 28:576-578.
80. Hammett T.M., Kling R., Johnston P., Liu W., Ngu D., Friedmann P., et al. Patterns of HIV prevalence and HIV risk behaviors among injection drug users prior to and 24 months following implementation of cross-border HIV prevention interventions in northern Vietnam and southern China. AIDS Education and Prevention 2006, 18:97-115.
81. Hart G.J., Carvell A.L., Woodward N., Johnson A.M., Williams P., Parry J.V. Evaluation of needle exchange in central London: Behaviour change and anti-HIV status over one year. AIDS 1989, 3:261-265.
82. Hartel D.M., Schoenbaum E.E. Methadone treatment protects against HIV infection: Two decades of experience in the Bronx, New York City. Public Health Reports 1998, 113:107-115.
83. Hartgers C., Buning E.C., van Santen G.W., Verster A.D., Coutinho R.A. The impact of the needle and syringe-exchange programme in Amsterdam on injecting risk behaviour. AIDS 1989, 3:571-576.
84. Hartgers C., van Ameijden E.J., van den Hoek J.A., Coutinho R.A. Needle sharing and participation in the Amsterdam Syringe Exchange program among HIV-seronegative injecting drug users. Public Health Reports 1992, 107:675-681.
85. Hedrich D. European report on drug consumption rooms 2004, European Monitoring Centre for Drug and Drug Addiction, Lisbon.
86. Heimer R., Clair S., Grau L.E., Bluthenthal R.N., Marshall P.A., Singer M. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 2002, 97:1277-1287.
87. Heimer R., Khoshnood K., Bigg D., Guydish J., Junge B. Syringe use and reuse: Effects of syringe exchange programs in four cities. Journal of Acquired Immune Deficiency Syndromes, 1998/07/15 1998, S37-S44.
88. Heinemann A., Gross U. Prevention of blood-brone virus infections among drug users in an open prison by syringe vending machines. Sucht 2001, 47:57-65.
89. Herbst J.H., Kay L.S., Passin W.F., Lyles C.M., Crepaz N., Marin B.V. A systematic review and meta-analysis of behavioral interventions to reduce HIV risk behaviors of hispanics in the United States and Puerto Rico. AIDS & Behavior 2007, 11:25-47.
90. Hernandez-Aguado I., Ramos-Rincon J.M., Avinio M.J., Gonzalez-Aracil J., Perez-Hoyos S., de la Hera M.G. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. European Journal of Epidemiology 2001, 17:539-544.
91. Holtzman D., Barry V., Ouellet L.J., Des Jarlais D.C., Vlahov D., Golub E.T., et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Preventive Medicine 2009, 49:68-73.
92. Hong Y., Li X. HIV/AIDS behavioral interventions in China: A literature review and recommendation for future research. AIDS and Behavior 2009, 13:603-613.
93. Hunter G.M., Donoghoe M.C., Stimson G.V., Rhodes T., Chalmers C.P. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. AIDS 1995, 9:493-501.
94. Huo D., Bailey S.L., Garfein R.S., Ouellet L.J. Changes in the sharing of drug injection equipment among street-recruited injection drug users in Chicago, Illinois, 1994-1996. Substance Use & Misuse 2005, 40:63-76.
95. Huo D., Ouellet L.J. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. Journal of Acquired Immune Deficiency Syndromes 2007, 45:108-114.
96. Hutchinson S.J., McIntyre P.G., Molyneaux P., Cameron S., Burns S., Taylor A., et al. Prevalence of hepatitis C among injectors in Scotland 1989-2000: Declining trends among young injectors halt in the late. Epidemiology and Infection 2002, 128:473-477.
97. Iguchi M.Y. Drug abuse treatment as HIV prevention: Changes in social drug use patterns might also reduce risk. Journal of Addictive Diseases 1998, 17:9-18.
98. Ingold F.R., Ingold S. The effects of the liberalisation of syringe sales on the behaviour of intravenous drug users in France. Bulletin of Narcotics 1989, 1:67-81.
99. Islam M., Stern T., Conigrave K.M., Wodak A. Client satisfaction and risk behaviours of the users of syringe dispensing machines: A pilot study. Drug and Alcohol Reviews 2008, 27:13-19.
100. Islam M., Wodak A., Conigrave K.M. The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings. International Journal of Drug Policy 2008, 19:436-441.
101. Islam M.M., Conigrave K.M. Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): A review. Harm Reduction Journal 2007, 4:14.
102. Jones L., Pickering L., Sumnall H., McVeigh J., Bellis M.A. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. International Journal of Drug Policy 2010, 21:335-342.
103. Keene J., Stimson G.V., Jones S., Parry-Langdon N. Evaluation of syringe-exchange for HIV prevention among injecting drug users in rural and urban areas of Wales. Addiction 1993, 88:1063-1070.
104. Kelly M., Swann C., Killoran A., Naidoo B., Barnett-Page E., Morgan A. Methodological problems in constructing the evidence base in public health 2002, Health Development Agency, London.
105. Kerr T., Kimber J., Debeck K., Wood E. The role of safer injection facilities in the response to HIV/AIDS among injection drug users. Current HIV/AIDS Reports 2007, 4:158-164.
106. Kerr T., Tyndall M., Li K., Montaner J., Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005, 366:316-318.
107. Khoshnood K., Blankenship K.M., Pollack H.A., Roan C.T., Altice F.L. Syringe source, use, and discard among injection-drug users in New Haven, Connecticut. AIDS Public Policy Journal 2000, 15:88-94.
108. Kimber J., Dolan K., Van Beek I., Hedrich D., Zurhold H. Drug consumption facilities: An update since 2000. Drug and Alcohol Review 2003, 22:227-233.
109. Kimber J., Palmateer N., Hutchinson S., Hickman M., Goldberg D., Rhodes T. Harm reduction among injecting drug users-Evidence of effectiveness. European Monitoring Centre for Drugs and Drug Addiction, Lisbon 2010, 115-163.
110. King V.L., Kidorf M.S., Stoller K.B., Brooner R.K. Influence of psychiatric comorbidity on HIV risk behaviors: Changes during drug abuse treatment. Journal of Addictive Diseases 2000, 19:65-83.
111. Kipke M.D., Unger J.B., Palmer R., Edgington R. Drug injecting street youth: A comparison of HIV risk-injection behaviors between needle exchange users and non-users. AIDS and Behaviour 1997, 1:225-232.
112. Klee H., Faugier J., Hayes C., Morris J. The sharing of injecting equipment among drug users attending prescribing clinics and those using needle-exchanges. British Journal of Addiction 1991, 86:217-223.
113. Klee H., Morris J. The role of needle exchanges in modifying sharing behaviour: Cross-study comparisons 1989-1993. Addiction 1995, 90:1635-1645.
114. Kretzschmar M., Wiessing L. Modelling the spread of HIV in social networks of injecting drug users. AIDS 1998, 12(7):801-811.
115. Kumar M.S., Mudaliar S., Daniels D. Community-based outreach HIV intervention for street-recruited drug users in Madras, India. Public Health Reports 1998, 113(Suppl. 66).
116. Kwiatkowski C.F., Booth R.E. Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2001, 26:483-489.
117. Lamden K.H., Kennedy N., Beeching N.J., Lowe D., Morrison C.L., Mallinson H., et al. Hepatitis B and hepatitis C virus infections: Risk factors among drug users in Northwest England. Journal of Infection 1998, 37:260-269.
118. Latkin C.A. Outreach in natural settings: The use of peer leaders for HIV prevention among injecting drug users' networks. Public Health Reports 1998, 113(Suppl. 9).
119. Latkin C.A., Sherman S., Knowlton A. HIV prevention among drug users: Outcome of a network-oriented peer outreach intervention. Health Psychology 2003, 22:339.
120. Li J., Luo J., Yang F. Evaluation on peer education program among injecting drug users. Zhonghua Liu Xing Bing Xue Za Zhi 2001, 22:334-336.
121. Longshore D., Bluthenthal R.N., Stein M.D. Needle exchange program attendance and injection risk in Providence Rhode Island. AIDS Education and Prevention 2001, 13:78-90.
122. Longshore D., Hsieh S., Danila B., Anglin M.D. Methadone maintenance and needle/syringe sharing. International Journal of the Addictions 1993, 28:983-996.
123. Lott D.C., Strain E.C., Brooner R.K., Bigelow G.E., Johnson R.E. HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone: "Erratum". Journal of Substance Abuse Treatment 2006, 31(3):317.
124. MacArthur G.J., Hickman M. Evidence for the effectiveness of interventions to prevent infections in people who inject drugs. Drug treatment for preventing hepatitis C, HIV and injecting risk behaviour. ECDC and EMCDDA Technical report 2011, European Centre for Disease Control and Prevention and European Monitoring Centre for Drugs and Drug Addiction, Stockholm.
125. MacDonald M.A., Wodak A.D., Dolan K.A., Van Beek I., Cunningham P.H., Kaldor J.M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs. Medical Journal 2000, 172:57-61.
126. Magura S., Kang S.Y., Nwakeze P.C., Demsky S. Temporal patterns of heroin and cocaine use among methadone patients. Substance Use and Misuse 1998, 33:2441-2467.
127. Magura S., Siddiqi Q., Shapiro J., Grossman J.I., Lipton D.S., Marion I.J., et al. Outcomes of an AIDS prevention program for methadone patients. International Journal of the Addictions 1991, 26:629-655.
128. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101:1499-1508.
129. Mandell W., Vlahov D., Latkin C.A., Carran D., Oziemkowska M.J., Reedt L. Changes in HIV risk behaviors among counseled injecting drug users. Journal of Drug Issues 1994, 24:555-567.
130. Mansson A.S., Moestrup T., Nordenfelt E., Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scandinavian Journal of Infectious Diseases 2000, 32:253-258.
131. Margolin A., Avants S.K., Warburton L.A., Hawkins K.A., Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychology 2003, 22:223-228.
132. Mark H.D., Nanda J., Davis-Vogel A., Navaline H., Scotti R., Wickrema R., et al. Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs. Public Health Nursing 2006, 23:11-19.
133. Marsch L.A., Bickel W.K., Badger G.J., Jacobs E.A. Buprenorphine treatment for opioid dependence: The relative efficacy of daily, twice and thrice weekly dosing. Drug & Alcohol Dependence 2005, 77:195-204.
134. Mathers B. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
135. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. [Review] [22 refs]. Lancet 2008, 372:1733-1745.
136. Meandzija B., O'Connor P.G., Fitzgerald B., Rounsaville B.J., Kosten T.R. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug & Alcohol Dependence 1994, 36:109-113.
137. Medley A., Kennedy C., O'Reilly K., Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: A systematic review and meta-analysis. AIDS Education and Prevention 2009, 21:181-206.
138. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes 1993, 6:1049-1056.
139. Miller C.L., Tyndall M., Spittal P., Li K., Laliberte N., Schechter M.T. HIV incidence and associated risk factors among young injection drug users. AIDS 2002, 16:491-493.
140. Miller C.L., Tyndall M., Spittal P., Li K., Palepu A., Schechter M.T. Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges. Journal of Urban Health 2002, 79:257-265.
141. Miller C.L., Wood E., Spittal P.M., Li K., Frankish J.C., Braitstein P., et al. The future face of coinfection: Prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2004, 36:743-749.
142. Monterroso E.R., Hamburger M.E., Vlahov D., Des Jarlais D.C., Ouellet L.J., Altice F.L., et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). Journal of Acquired Immune Deficiency Syndromes 2000, 25:63-70.
143. Morissette C., Cox J., De P., Tremblay C., Roy E., Allard R., et al. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: Implications for HIV and hepatitis C prevention. International Journal of Drug Policy 2007, 18:204-212.
144. Moss A.R., Vranizan K., Gorter R., Bacchetti P., Watters J., Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994, 8:223-231.
145. MSIC Evaluation Committee Final report of the evaluation of the Sydney Medically Supervised Injecting Centre, Sydney 2003, Available from, (accessed on 27 June 2011). http://www.druginfo.nsw.gov.au/__data/page/1229/NDARC_final_evaluation_report4.pdf.
146. Nacopoulos A.G., Lewtas A.J., Ousterhout M.M. Syringe exchange programs: Impact on injection drug users and the role of the pharmacist from a U.S. perspective. Journal of the American Pharmacists Association 2010, 50:148-157.
147. National Institute on Drug Abuse Outreach/risk reduction strategies for changing HIV-related risk behaviors among injection drug users: The National AIDS Demonstration Research (NADR) Project 1994.
148. Navaline H.A., Snider E.C., Petro C.J. An automated version of the risk assessment battery (RAB): Enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses 1994, 10:S281-S283.
149. Neaigus A., Sufian M., Friedman S.R., Goldsmith D.S., Stepherson B., Mota P., et al. Effects of outreach intervention on risk reduction among intravenous drug users. AIDS Education & Prevention 1990, 2:253-271.
150. Neaigus A., Zhao M., Gyarmathy V.A., Cisek L., Friedman S.R., Baxter R.C. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. Journal of Urban Health 2008, 85:309-322.
151. Needle R.H., Burrows D., Friedman S.R., Dorabjee J., Touze G., Badrieva L., et al. Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users. International Journal of Drug Policy 2005, 16:S45-S57.
152. Nejedly M.M., Burki C. Monitoring HIV risk behaviors in a street agency with injecting room in Switzerland 1996, 1996. Medizinischen Facultat, Universitat Bern, Bern.
153. Nelson K.E., Vlahov D., Cohn S., Lindsay A., Solomon L., Anthony J.C. Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA 1991, 266:2259-2261.
154. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet 2011, 378:571-583.
155. Novick D., Joseph H., Salsitz E., Wang G., Richman B., Poretsky L., et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Archives of Internal Medicine 1990, 150:97-99.
156. Obadia Y., Feroni I., Perrin V., Vlahov D., Moatti J.P. Syringe vending machines for injection drug users: An experiment in Marseille France. American Journal of Public Health 1999, 89:1852-1854.
157. Oliver K., Maynard H., Friedman S.R. Behavioral and community impact of the Portlandsyringe exchange programm. Proceedings: Workshop on needle exchange and bleach distribution programs 1994, 35-46. National Academy Press, Washington DC. J. Normand, D. Vlahov, L.E. Moses (Eds.).
158. Ouellet L., Huo D., Bailey S.L. HIV risk practices among needle exchange users and nonusers in Chicago. Journal of Acquired Immune Deficiency Syndromes 2004, 37:1187-1196.
159. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of harm reduction interventions in preventing hepatitis C transmission among injecting drug users 2008, Prevention Working Groups of the Advisory Council of the Misuse of Drugs and the Hepatitis C Action Plan for Scotland, Glasgow.
160. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction 2010, 105:844-859.
161. Paone D., Des Jarlais C., Caloir S. New York syringe exchange; an overview. Proceedings of a workshop on needle exchange and bleach distribution programs 1994, 47-63. National Academy Press, Washington DC. J. Normand, D. Vlahov, L.E. Moses (Eds.).
162. Patrick D.M., Tyndall M.W., Cornelisse P.G.A., Li K., Sherlock C.H., Rekart M.L., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Cmaj 2001, 165:889-895.
163. Peak A., Rana S., Maharjan S.H., Jolley D., Crofts N. Declining risk for HIV among injecting drug users in Kathmandu, Nepal: The impact of a harm-reduction programme. AIDS 1995, 9:1067-1070.
164. Pouget E.R., Deren S., Fuller C.M., Blaney S., McMahon J.M., Kang S.Y., et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. Journal of Acquired Immune Deficiency Syndromes 2005, 39:471-477.
165. Power R., Nozhkina N. The value of process evaluation in sustaining HIV harm reduction in the Russian Federation. AIDS 2002, 16:303-304.
166. Prendergast M.L., Urada D., Podus D. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. Journal of Consulting & Clinical Psychology 2001, 69:389-405.
167. Reyes Fuentes V.C. 15 Jahre Fixerraum Bern. Auswirkungen auf soziale und medizinische Aspekte bei Drogenabhängigen. Dissertation at the medical faculty of the university in Bern, under the supervision of Dr med Robert Hämmig 2003.
168. Rezza G., Sagliocca L., Zaccarelli M., Nespoli M., Siconolfi M., Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scandinavian Journal of Infectious Disease 1996, 28(1):27-29.
169. Rhoades H., Creson D., Elk R., Schmitz J., Grabowski J. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health 1998, 88:34-39.
170. Rhodes T., Judd A., Mikhailova L., Sarang A., Khutorskoy M., Platt L., et al. Injecting equipment sharing among injecting drug users in Togliatti City, Russian Federation: Maximizing the protective effects of syringe distribution. Journal of Acquired Immune Deficiency Syndromes 2004, 35:293-300.
171. Richard A.J., Mosier V., Atkinson J.S. New syringe acquisition and multi-person use of syringes among illegal drug users. Journal of Public Health Policy 2002, 23:324-343.
172. Robles R.R., Feliciano C., Colon H.M., Aponte L. Puerto Rico AIDS Prevention Project (Rep. No. PRAPP; Final report submitted to the National Institute on Drug Abuse) 1993, National Institute on Drug Abuse, Washington D.C.
173. Robles R.R., Reyes J.C., Colo H.M., Sahai H., Marrero C.A., Matos T.D., et al. Effects of combined counseling and case management to reduce HIV risk behaviors among Hispanic drug injectors in Puerto Rico. Journal of Substance Abuse Treatment 2004, 27:145-152.
174. Ronco C., Spuhler G., Kaiser R. Evaluation des 'Aufenhalts-and Betreuungsraum für Drogenabhängige' in Luzern. Sozial-und Präventivemedizin 1996, 41:S45-S57.
175. Roy K.M., Hutchinson S.J., Wadd S., Taylor A., Cameron S.O., Burns S., et al. Hepatitis C virus infection among injecting drug users in Scotland: A review of prevalence and incidence data and the methods used to generate them. Epidemiology and Infection 2006, 135:433-442.
176. Ruan Y., Qin G., Yin L., Chen K., Qian H.-Z., Hao C., et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: A 3-year follow-up study. AIDS 2007, 21(Suppl. 8 (December)).
177. Sacks-Davis R., Horyniak D., Grebely J., Hellard M. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review. International Journal of Drug Policy 2011, 10.1016/j.drugpo.2011.08.002.
178. Sarang A., Rhodes T., Platt L. Access to syringes in three Russian cities: Implications for syringe distribution and coverage. International Journal of Drug Policy 2008, 19:S25-S36.
179. Sarkar K., Mitra S., Bal B., Chakraborty S., Bhattacharya S.K. Rapid spread of hepatitis C and needle exchange programme in Kolkata India. Lancet 2003, 361:1301-1302.
180. Saxon A.J., Calsyn D.A., Jackson T.R. Longitudinal changes in injection behaviors in a cohort of injection drug users. Addiction 1994, 89:191-202.
181. Schilling R.F., Fernando D., Fontdevila J., El-Bassel N. HIV risk reduction among injection drug users: Explaining the lack of anticipated outcomes in a community-level controlled comparison study. Evaluation and Program Planning 2000, 23:301-313.
182. Schoenbaum E.E., Hartel D.M., Gourevitch M.N. Needle exchange use among a cohort of injecting drug users. AIDS 1996, 10:1729-1734.
183. Schroeder J.R., Epstein D.H., Umbricht A., Preston K.L. Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addictive Behaviors 2006, 31:868-879.
184. Sears C., Guydish J.R., Weltzien E.K., Lum P.J. Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California U. S. A. Journal of Acquired Immune Deficiency Syndromes 2001, 27:193-201.
185. Sears C., Weltzien E., Guydish J. A cohort study of syringe exchangers and nonexchangers in San Francisco. Journal of Drug Issues 2001, 13:445-464.
186. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA 2000, 283:1303-1310.
187. Selvey L.A., Denton M., Plant A.J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Australian and New Zealand Journal of Public Health 1997, 21:102-104.
188. Sergeyev B., Oparina T., Rumyantseva T., Volkanevskii V., Broadhead R., Heckathorn D., et al. HIV prevention in Yaroslavl, Russia: A peer-driven intervention and needle exchange. Journal of Drug Issues 1999, 29:777-804.
189. Serpelloni G., Carrieri M.P., Rezza G., Morganti S., Gomma M., Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: A nested case-control study. AIDS Care 1994, 6:215-220.
190. Sharma M., Burrows D., Bluthenthal R. Coverage of HIV prevention programmes for injection drug users: Confusions, aspirations, definitions and ways forward. International Journal of Drug Policy 2007, 18:92-98.
191. Shore R.E., Marmor M., Titus S., Des Jarlais D.C. Methadone maintenance and other factors associated with intraindividual temporal trends in injection-drug use. Journal of Substance Abuse Treatment 1996, 13:248.
192. Simpson D.D., Joe G.W., Rowan-Szal G., Greener J. Client engagement and change during drug abuse treatment. Journal of Substance Abuse 1995, 7:117-134.
193. Singer M., Himmelgreen D., Weeks M.R., Radda K.E., Martinez R. Changing the environment of AIDS risk: Findings on syringe exchange and pharmacy sales of syringes in Hartford CT. Medical Anthropology 1997, 18:107-130.
194. Smyth B.P., Keenan E., O'Connor J.J. Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. Journal of Epidemiology and Community Health 1999, 53:434-435.
195. Somaini B., Wang J., Perozo M., Kuhn F., Meili D., Grob P., et al. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care 2000, 12:449-460.
196. Sorensen J.L., Copeland A.L. Drug abuse treatment as an HIV prevention strategy: A review. [Review] [70 refs]. Drug & Alcohol Dependence 2000, 59:17-31.
197. Sorensen J.L., London J., Heitzmann C., Gibson D.R., Morales E.S., Dumontet R., et al. Psychoeducational group approach: HIV risk reduction in drug users. AIDS Education & Prevention 1994, 6:95-112.
198. Stark K., Muller R., Bienzle U., Guggenmoos-Holzmann I. Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin. Journal of Epidemiology & Community Health 1996, 50:534-537.
199. Stein M.D., Anderson B., Charuvastra A., Maksad J., Friedmann P.D. A brief intervention for hazardous drinkers in a needle exchange program. Journal of Substance Abuse Treatment 2002, 22:23-31.
200. Sterk C.E., Theall K.P., Elifson K.W., Kidder D. HIV risk reduction among African-American women who inject drugs: A randomized controlled trial. AIDS and Behavior 2003, 7:73-86.
201. Stoltz J.A., Wood E., Small W., Li K., Tyndall M., Montaner J., et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. Journal of Public Health (Oxf) 2007, 29:35-39.
202. Strang J., Marsden J., Cummins M., Farrell M., Finch E., Gossop M., et al. Randomized trial of supervised injectable versus oral methadone maintenance: Report of feasibility and 6-month outcome. Addiction 2000, 95:1631-1645.
203. Strathdee S.A., Patrick D.M., Archibald C.P., Ofner M., Cornelisse P.G., Rekart M., et al. Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction 1997, 92:1339-1347.
204. Strathdee S.A., Patrick D.M., Currie S.L., Cornelisse P.G., Rekart M.L., Montaner J.S., et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59-F65.
205. Taylor A., Goldberg D., Hutchinson S., Cameron S., Gore S.M., McMenamin J., et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: Are current harm reduction strategies working?. Journal of Infection 2000, 40:176-183.
206. Teesson M., Ross J., Darke S., Lynskey M., Ali R., Ritter A., et al. One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug & Alcohol Dependence 2006, 83:174-180.
207. Thiede H., Hagan H., Murrill C.S. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health 2000, 77:331-345.
208. Tilson H., Aramrattana A., Bozzette S.A., Celentano D.D., Falco M., Hammett T.M., et al. Preventing HIV infection among injecting drug users in high-risk countries: An assessment of the evidence 2007, Institute of Medicine, Washington.
209. Trubnikov M.N., Khodakevich L.N., Barkov D.A., Blagovo D.V. Sources of injecting equipment for drug users in Moscow Russia. International Journal of Drug Policy 2003, 14:453-455.
210. Turner K., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of Hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 2011, 106:1978-1988.
211. van Ameijden E.J., Coutinho R.A. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998, 12:625-633.
212. van Ameijden E.J., van den Hoek A.R., Coutinho R.A. Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. American Journal of Public Health 1994, 84:275-281.
213. van Ameijden E.J., van den Hoek J.A., Mientjes G.H., Coutinho R.A. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. European Journal of Epidemiology 1993, 9:255-262.
214. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102:1454-1462.
215. van den Hoek J.A., van Haastrecht H.J., Coutinho R.A. Risk reduction among intravenous drug users in Amsterdam under the influence of AIDS. American Journal of Public Health 1989, 79:1355-1357.
216. Vazirian M., Nassirimanesh B., Zamani S., Ono-Kihara M., Kihara M., Ravari S.M., et al. Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran Iran: A cross-sectional study. Harm Reduction Journal 2005, 2:19.
217. Vertefeuille J., Marx M.A., Tun W., Huettner S., Strathdee S.A., Vlahov D. Decline in self-reported high-risk injection-related behaviors among HIV-seropositive participants in the Baltimore needle exchange program. AIDS and Behavior 2000, 4:381-388.
218. Vickerman P., Hickman M., Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007, 36:396-405.
219. Vlahov D., Junge B., Brookmeyer R., Cohn S., Riley E., Armenian H., et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997, 16:400-406.
220. Voytek C., Sherman S.G., Junge B. A matter of convenience: Factors influencing secondary syringe exchange in Baltimore, Maryland USA. International Journal of Drug Policy 2003, 14:465-467.
221. Ward J., Darke S., Hall W. The HIV risk-taking behaviour scale manual 1990, National Drug and Alcohol Research Centre, Sydney, Australia.
222. Watters J.K., Estilo M.J., Clark G.L., Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994, 271:115-120.
223. Wiebel W.W., Jimenez A., Johnson W., Ouellet L., Jovanovic B., Lampinen T., et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1996, 12:282-289.
224. Wiessing L., Likatavicius G., Hedrich D., Guarita B., van den Laar M.J., Vicente J. Trends in HIV and hepatitis c virus infections among injecting drug users in Europe. 2005-2010. Eurosurveillance 2011, 16. pii: 20031.
225. Wiessing L., van de Laar M.J., Donoghoe M.C., Guarita B., Klempova D., Griffiths P. HIV among injecting drug users in Europe: Increasing trends in the East. Eurosurveillance 2008, 13. pii: 19067.
226. Williams A.B., McNelly E.A., Williams A.E., D'Aquila R.T. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care 1992, 4:35-41.
227. Williams C.T., Metzger D.S. Race and distance effects on regular syringe exchange program use and injection risks: A geobehavioral analysis. American Journal of Public Health 2010, 100:1068-1074.
228. Wodak A., Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users 2004, World Health Organization, Geneva.
229. Wong J.B., McQuillan G.M., McHutchison J.G., Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 2000, 90:1562-1569.
230. Wood E. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. Canadian Medical Association Journal 2006, 175:1399-1404.
231. Wood E., Kerr T., Spittal P.M., Small W., Tyndall M.W., O'Shaughnessy M.V., et al. An external evaluation of a peer-run "unsanctioned" syringe exchange program. Journal of Urban Health 2003, 80:455-464.
232. Wood E., Tyndall M., Stolz J. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. American Journal of Infectious Disease 2005, 1:50-54.
233. Wood E., Tyndall M.W., Spittal P.M., Li K., Hogg R.S., Montaner J.S., et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS 2002, 16:941-943.
234. Wright N.M.J., Tompkins C.N.E. A review of the evidence for the effectiveness of primary prevention interventions for Hepatitis C among injecting drug users. Harm Reduction Journal 2006, 6:27.
235. Wu Z., Luo W., Sullivan S.G., Rou K., Lin P., Liu W., et al. Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China. AIDS 2007, 21:S115-S122.